

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CO14CIP DIV2SERIAL NO.
09/342,314INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

SEP 22 2000

APPLICANT
Michael J. Yellin et al.FILING DATE
June 29, 1999GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
<i>MB</i>	Alderson, M.R. et al. "CD40 Expression By Human Monocytes: Regulation By Cytokines And Activation Of Monocytes By The Ligand For CD40", <i>J. Exp. Med.</i> 178:669-674 (1993).
<i>f</i>	Bajorath J. et al. "Identification of Residues on CD40 and Its Ligand Which Are Critical for the Receptor-Ligand Interaction", <i>Biochemistry</i> 34:1833-1844 (1995).
	Banchereau J. et al. "The CD40 Antigen and its Ligand", <i>Annual Rev. Immunol.</i> 12:881-922 (1994).
	Biancone, L. et al. "Inhibition of the CD40-CD40Ligand Pathway Prevents Murine Membranous Glomerulonephritis", <i>Kidney Intl.</i> 48:458-468 (1995).
	Buhlmann, J.E. et al. "Therapeutic Potential For Blockade of the CD40 Ligand, gp39", <i>J. Clin. Immunol.</i> 16:83-89 (1996).
	Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", <i>Blood</i> 85(3):780-789 (1995).
	Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", <i>Proc. Natl. Acad. Sci., USA</i> 83:4494-4498 (1986).
	Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", <i>J. Immunol.</i> 155:3329-3337 (1995).
	Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", <i>Res. Immunol.</i> 145:200-205 (1994).
	Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", <i>Immunol. Today</i> 15:406-411 (1994).
	Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis With An Antibody to gp39, the Ligand for CD40", <i>Science</i> 261:1328-1330 (1993).
	Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", <i>J. Immunol.</i> 149:655-660 (1992).
	Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", <i>Proc. Natl. Acad. Sci., USA</i> 87:7698-7702 (1990).
	Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", <i>J. Immunol.</i> 149:775-782 (1992).
	Gray, D. et al "Memory B Cell Development But Not Germinal Center Formation is Impaired by In Vivo Blockade of CD40-CD40 Ligand Interaction", <i>J. Exp. Med.</i> 180:141-154 (1994).
	Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", <i>Eur. J. Of Immunol.</i> 24:1835-1842 (1994).
<i>MB</i>	Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", <i>J. Exp. Med.</i> 182:33-40 (1995).

EXAMINER

GAMMEL 3/24/01

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CO14CIP DIV2SERIAL NO.
09/342,314INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

SEP 22 2000

APPLICANT
Michael J. Yellin et al.FILING DATE
June 29, 1999GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
<i>ML</i>	Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", <i>Proc. Natl. Acad. Sci., USA</i> 92:4342-4346 (1995).
<i>1</i>	Karpusas, M. et al. "2 Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", <i>Structure</i> 3(10): 1031-1039 (1995).
	Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", <i>Science</i> 257:1078-1082 (1992).
	Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase I in Systemic Sclerosis", <i>J. Immunol.</i> 155:2703-2714 (1995).
	Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", <i>J. Neuroimmunology</i> 54:175 (1994).
	Larsen, C.P. et al. "CD40-gp39 Interactions Play A Critical Role During Allograft Rejection", <i>Transplantation</i> 61:4-9 (1996).
	Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", <i>Leukemia</i> 4(11):732-738 (1990).
	Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", <i>Res. Immunol.</i> 145:215-222 (1994).
	Mohan, C. et al. "Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis", <i>J. Immunol.</i> 154:1470-1480 (1995).
	Merck Manual of Diagnosis And Therapy, 16th Ed. "Idiopathic Infiltrative Diseases Of The Lungs", Merck Research Laboratories, Rahway, NJ 718-720 (1992).
	O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", <i>Am. J. Of Pathology</i> 144:(1):2126 (1994).
	Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", <i>Cancer Immunol. Immunother.</i> 20:23-28 (1985).
	Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", <i>Scand. J. Immunol.</i> 31:213-224 (1990).
	Stüber, E. et al. "Blocking The CD40L-CD40 Interaction In Vivo Specifically Prevents the Priming of T Helper 1 Cells Through The Inhibition of Interleukin 12 Secretion", <i>J. Exp. Med.</i> 183: 693-698 (1996).
	Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia As Well As B-Lineage Non-Hodgkin's Lymphoma Cells", <i>Blood</i> 76(12):2449-2456 (1990).
<i>W</i>	Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion In Multiple Myeloma", <i>Blood</i> 85:1903-1912 (1995).

EXAMINER

Gummer 3/29/01

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CO14CIP DIV2	SERIAL NO. 09/342,314
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Michael J. Yellin et al.	
		FILING DATE June 29, 1999	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

Fraser 3/24/61

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.